OneroRX Completes Recapitalization to Drive Growth
December 2023 – England & Company is pleased to announce that it served as the exclusive financial advisor and placement agent in the debt and equity recapitalization of OneroRx, Inc. (“OneroRx”). The financing, provided by Cyprium Investment Partners LLC (“Cyprium”) and Wells Fargo Bank, allowed OneroRx to realign its shareholder base and strengthen its balance sheet, and will enable it to continue to grow through acquisitions.
OneroRx, based in West Des Moines, IA, is a leading technology-enabled, integrated pharmacy services company operating community pharmacies and telepharmacies in underserved rural and urban areas in six states in the Midwest. In its locations, OneroRx maintains a smaller physical footprint than the national pharmacy chains and more efficient operations that enable the Company to better meet the needs of underserved communities and focus on clinical services rather than retail. The Company’s growth strategy incorporates acquisitions, building de novo sites, growing its patient base, and leveraging additional specialty services across its network.
“We have a robust M&A pipeline, and this transaction gives us the flexibility we need to position ourselves better to invest in growing the business,” said Joseph Dunham, OneroRx’s Chief Executive Officer. Dunham added, “The England team was critical in evaluating our alternatives, finding the right partners, and bringing this transaction together.”
About Cyprium
Cyprium is a private equity and mezzanine firm focused on non-controlling investments in profitable middle-market companies, allowing company owners and their management teams to retain a controlling interest in their businesses. Cyprium provides common equity, preferred stock, subordinated debt, or any combination thereof, offering flexibility and increasing the certainty of close. With offices in Cleveland, New York, and Chicago, the firm invests $5 million to $60 million per transaction in U.S. and Canadian companies with $4 million or more of EBITDA. For over 25 years, the team has deployed $1.9 billion in 100 platform investments.
OneroRX Completes Recapitalization to Drive Growth
December 2023 – England & Company is pleased to announce that it served as the exclusive financial advisor and placement agent in the debt and equity recapitalization of OneroRx, Inc. (“OneroRx”). The financing, provided by Cyprium Investment Partners LLC (“Cyprium”) and Wells Fargo Bank, allowed OneroRx to realign its shareholder base and strengthen its balance sheet, and will enable it to continue to grow through acquisitions.
OneroRx, based in West Des Moines, IA, is a leading technology-enabled, integrated pharmacy services company operating community pharmacies and telepharmacies in underserved rural and urban areas in six states in the Midwest. In its locations, OneroRx maintains a smaller physical footprint than the national pharmacy chains and more efficient operations that enable the Company to better meet the needs of underserved communities and focus on clinical services rather than retail. The Company’s growth strategy incorporates acquisitions, building de novo sites, growing its patient base, and leveraging additional specialty services across its network.
“We have a robust M&A pipeline, and this transaction gives us the flexibility we need to position ourselves better to invest in growing the business,” said Joseph Dunham, OneroRx’s Chief Executive Officer. Dunham added, “The England team was critical in evaluating our alternatives, finding the right partners, and bringing this transaction together.”
About Cyprium
Cyprium is a private equity and mezzanine firm focused on non-controlling investments in profitable middle-market companies, allowing company owners and their management teams to retain a controlling interest in their businesses. Cyprium provides common equity, preferred stock, subordinated debt, or any combination thereof, offering flexibility and increasing the certainty of close. With offices in Cleveland, New York, and Chicago, the firm invests $5 million to $60 million per transaction in U.S. and Canadian companies with $4 million or more of EBITDA. For over 25 years, the team has deployed $1.9 billion in 100 platform investments.